About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

NOTCH1 mutations, found in 20% of CLL cases, are associated with poor outcomes in chemotherapy but not yet in treatment guidelines. A retrospective analysis showed improved PFS for NOTCH1-mutated CLL ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...

Getting a diagnosis of leukemia can feel overwhelming. But multiple treatment options and support organizations can help you on your journey after diagnosis. Leukemia is a type of cancer that affects ...

This multicenter retrospective study leveraged artificial intelligence (AI) to analyze structured and unstructured data from four Belgian hospitals (January 1, 2018-October 31, 2021). Structured data ...

The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...